BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lewis EF, Claggett BL, Mcmurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail 2017;10. [DOI: 10.1161/circheartfailure.116.003430] [Cited by in Crossref: 83] [Cited by in F6Publishing: 29] [Article Influence: 16.6] [Reference Citation Analysis]
Number Citing Articles
1 Gori M, Januzzi JL, D'Elia E, Lorini FL, Senni M. Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. Card Fail Rev 2021;7:e06. [PMID: 33889425 DOI: 10.15420/cfr.2020.25] [Reference Citation Analysis]
2 Khariton Y, Fonarow GC, Arnold SV, Hellkamp A, Nassif ME, Sharma PP, Butler J, Thomas L, Duffy CI, DeVore AD, Albert NM, Patterson JH, Williams FB, McCague K, Spertus JA. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail 2019;7:933-41. [PMID: 31521679 DOI: 10.1016/j.jchf.2019.05.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
3 Shiota S, Kitagawa T, Hidaka T, Goto N, Mio N, Kanai K, Naka M, Togino H, Mochizuki M, Ochikubo H, Nakano Y, Kihara Y, Kimura H. The International Classification of Functioning, Disabilities, and Health categories rated as necessary for care planning for older patients with heart failure: a survey of care managers in Japan. BMC Geriatr 2021;21:704. [PMID: 34911480 DOI: 10.1186/s12877-021-02647-3] [Reference Citation Analysis]
4 Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Køber L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjöstrand M, Langkilde AM, McMurray JJV. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation 2020;141:90-9. [PMID: 31736335 DOI: 10.1161/CIRCULATIONAHA.119.044138] [Cited by in Crossref: 91] [Cited by in F6Publishing: 30] [Article Influence: 30.3] [Reference Citation Analysis]
5 Stogios N, Fezza G, Wong JV, Ross HJ, Farkouh ME, Nolan RP. Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome. Eur J Heart Fail 2021;23:205-7. [PMID: 33619798 DOI: 10.1002/ejhf.2139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hlavatá K, Hošková L, Franeková J, Jabor A, Kautzner J, Melenovský V, Beneš J. Transition from angiotensin-converting enzyme inhibitor/angiotensin-II-receptor-blocker to sacubitril/valsartan in chronic heart failure patients: Initial experiences in clinical practice. Cor Vasa 2018;60:e209-14. [DOI: 10.1016/j.crvasa.2017.10.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Zamora E, González B, Lupón J, Borrellas A, Domingo M, Santiago-Vacas E, Cediel G, Codina P, Rivas C, Pulido A, Crespo E, Velayos P, Diaz V, Bayes-Genis A. Quality of life in patients with heart failure and improved ejection fraction: one-year changes and prognosis. ESC Heart Fail 2022. [PMID: 35916351 DOI: 10.1002/ehf2.14098] [Reference Citation Analysis]
8 Sandhu AT, Kohsaka S, Turakhia MP, Lewis EF, Heidenreich PA. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction. JAMA Cardiol 2021. [PMID: 34757380 DOI: 10.1001/jamacardio.2021.4585] [Reference Citation Analysis]
9 Wachter R, Klebs S, Balas B, Kap E, Engelhard J, Schlienger R, Bruce Wirta S, Fonseca AF. Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany. ESC Heart Fail 2020;7:2318-30. [PMID: 33121216 DOI: 10.1002/ehf2.12768] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Książczyk M, Lelonek M. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings. Heart Fail Rev 2020;25:393-402. [PMID: 31713710 DOI: 10.1007/s10741-019-09879-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Mai Ba H, Son YJ, Lee K, Kim BH. Transitional Care Interventions for Patients with Heart Failure: An Integrative Review. Int J Environ Res Public Health 2020;17:E2925. [PMID: 32340346 DOI: 10.3390/ijerph17082925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
12 Piamjariyakul U, Petitte T, Smothers A, Wen S, Morrissey E, Young S, Sokos G, Moss AH, Smith CE. Study protocol of coaching end-of-life palliative care for advanced heart failure patients and their family caregivers in rural appalachia: a randomized controlled trial. BMC Palliat Care 2019;18:119. [PMID: 31884945 DOI: 10.1186/s12904-019-0500-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
13 Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol 2018;3:498-505. [PMID: 29617523 DOI: 10.1001/jamacardio.2018.0398] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 16.3] [Reference Citation Analysis]
14 Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, Vader J. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019;24:167-176. [PMID: 30565021 DOI: 10.1007/s10741-018-9757-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
15 McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 2019;21:665-75. [PMID: 30895697 DOI: 10.1002/ejhf.1432] [Cited by in Crossref: 110] [Cited by in F6Publishing: 87] [Article Influence: 36.7] [Reference Citation Analysis]
16 Berliner D, Hänselmann A, Bauersachs J. The Treatment of Heart Failure with Reduced Ejection Fraction. Dtsch Arztebl Int 2020;117:376-86. [PMID: 32843138 DOI: 10.3238/arztebl.2020.0376] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
17 Felker GM, Sharma A, Mentz RJ, She L, Green CL, Granger BB, Heitner JF, Cooper L, Teuteberg J, Grodin JL, Rosenfield K, Hudson L, Kwee LC, Ilkayeva O, Shah SH. A randomized controlled trial of mobile health intervention in patients with heart failure and diabetes. J Card Fail 2022:S1071-9164(22)00649-2. [PMID: 35882260 DOI: 10.1016/j.cardfail.2022.07.048] [Reference Citation Analysis]
18 Gaudino M, Chikwe J, Bagiella E, Bhatt DL, Doenst T, Fremes SE, Lawton J, Masterson Creber RM, Sade RM, Zwischenberger BA; American Heart Association Council on Cardiovascular Surgery and Anesthesia. Methodological Standards for the Design, Implementation, and Analysis of Randomized Trials in Cardiac Surgery: A Scientific Statement From the American Heart Association. Circulation 2021;:CIR0000000000001037. [PMID: 34865513 DOI: 10.1161/CIR.0000000000001037] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Khan MS, Friede T, Anker SD, Butler J. Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis. ESC Heart Fail 2021;8:1885-91. [PMID: 33784028 DOI: 10.1002/ehf2.13301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Rubio Campal JM, Del Castillo H, Arroyo Rivera B, de Juan Bitriá C, Taibo Urquia M, Sánchez Borque P, Miracle Blanco Á, Bravo Calero L, Martí Sánchez D, Tuñón Fernández J. Improvement in quality of life with sacubitril/ /valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry. Cardiol J 2021;28:402-10. [PMID: 33634846 DOI: 10.5603/CJ.a2021.0009] [Reference Citation Analysis]
21 Liang B, Zhao YX, Zhang XX, Liao HL, Gu N. Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol 2020;19:55. [PMID: 32375806 DOI: 10.1186/s12933-020-01024-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
22 Holmlund L, Brännström M, Lindmark K, Sandberg C, Hellström Ängerud K. Health-related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan. Nurs Open 2020;7:556-62. [PMID: 32089852 DOI: 10.1002/nop2.420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Barman HA, Tanyolaç S, Dogan O, Bal E, Atıcı A, Özyıldırım S, Yiğit Z. Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction. Clin Drug Investig 2022;42:533-40. [PMID: 35635714 DOI: 10.1007/s40261-022-01161-7] [Reference Citation Analysis]
24 Thomas M, Khariton Y, Fonarow GC, Arnold SV, Hill L, Nassif ME, Chan PS, Butler J, Thomas L, DeVore AD, Hernandez AF, Albert NM, Patterson JH, Williams FB, Spertus JA. Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction. ESC Heart Fail 2021;8:2670-8. [PMID: 33932120 DOI: 10.1002/ehf2.13298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Reza N, Butler J. Assessing health status after discharge for decompensated heart failure: a patient-centred priority. Eur J Heart Fail 2022. [PMID: 35481937 DOI: 10.1002/ejhf.2521] [Reference Citation Analysis]
26 Perrone-filardi P, Paolillo S, Agostoni P, Basile C, Basso C, Barillà F, Correale M, Curcio A, Mancone M, Merlo M, Metra M, Muscoli S, Nodari S, Palazzuoli A, Pedrinelli R, Pontremoli R, Senni M, Volpe M, Indolfi C, Sinagra G. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.04.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail 2019;21:337-41. [PMID: 30741494 DOI: 10.1002/ejhf.1402] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 18.0] [Reference Citation Analysis]
28 Mentz RJ, Xu H, O'Brien EC, Thomas L, Alexy T, Gupta B, Vilaro J, Lala A, DeVore AD, Dhingra R, Briasoulis A, Simon MA, Stehlik J, Rodgers JE, Dunlay SM, Abshire M, Wells QS, Barringhaus KG, Eckman PM, Lowes BD, Espinoza J, Blanco R, Shen X, Duffy CI, Hernandez AF. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. Am Heart J 2020;230:35-43. [PMID: 32980364 DOI: 10.1016/j.ahj.2020.09.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Raschi E, Diemberger I, Sabatino M, Poluzzi E, De Ponti F, Potena L. Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. Expert Opin Pharmacother 2022;:1-18. [PMID: 35050813 DOI: 10.1080/14656566.2022.2027909] [Reference Citation Analysis]
30 Khandwalla RM, Birkeland K, Heywood JT, Steinhubl S, McCague K, Fombu E, Grant D, Riebman JB, Owens RL. Activity Sensors to Evaluate the Effect of Sacubitril/Valsartan on Quality-of-Life in Heart Failure: rational and design of the AWAKE-HF study. ESC Heart Fail 2019;6:1313-21. [PMID: 31638338 DOI: 10.1002/ehf2.12514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF; EVALUATE-HF Investigators. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA 2019;322:1077-84. [PMID: 31475296 DOI: 10.1001/jama.2019.12843] [Cited by in Crossref: 124] [Cited by in F6Publishing: 97] [Article Influence: 41.3] [Reference Citation Analysis]
32 Lau CW, Martens P, Lambeets S, Dupont M, Mullens W. Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients. Acta Cardiol 2019;74:405-12. [PMID: 30474478 DOI: 10.1080/00015385.2018.1521054] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
33 Ambrosy AP, Velazquez EJ. Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. Am Heart J 2018;199:176-7. [PMID: 29754658 DOI: 10.1016/j.ahj.2018.02.007] [Reference Citation Analysis]
34 Jankowska EA, Kirwan BA, Kosiborod M, Butler J, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Filippatos G, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Friede T, Fabien V, Dorigotti F, Pocock S, Ponikowski P. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J 2021:ehab234. [PMID: 34080008 DOI: 10.1093/eurheartj/ehab234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kujath AS, Frei J. Orthopaedic Nursing and Heart Failure: A Review of Pathophysiology and Management. Orthop Nurs 2022;41:25-34. [PMID: 35045539 DOI: 10.1097/NOR.0000000000000818] [Reference Citation Analysis]
36 Berliner D, Bauersachs J. New drugs: big changes in conservative heart failure therapy? Eur J Cardiothorac Surg. 2019;55:i3-i10. [PMID: 31106335 DOI: 10.1093/ejcts/ezy421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Vaduganathan M, Fonarow GC, Greene SJ, DeVore AD, Albert NM, Duffy CI, Hill CL, Spertus JA, Thomas LE, Butler J. Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. J Am Coll Cardiol 2019;74:3176-8. [PMID: 31727426 DOI: 10.1016/j.jacc.2019.10.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Mann DL, Felker GM. Mechanisms and Models in Heart Failure: A Translational Approach. Circ Res 2021;128:1435-50. [PMID: 33983832 DOI: 10.1161/CIRCRESAHA.121.318158] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Hunger M, Eriksson J, Regnier SA, Mori K, Spertus JA, Cristino J. Mapping the Kansas City Cardiomyopathy Questionnaire (KCCQ) Onto EQ-5D-3L in Heart Failure Patients: Results for the Japanese and UK Value Sets. MDM Policy Pract 2020;5:2381468320971606. [PMID: 33344768 DOI: 10.1177/2381468320971606] [Reference Citation Analysis]
40 Dereli S, Kılınçel O, Çerik İB, Kaya A. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction. Acta Cardiol 2020;75:774-82. [PMID: 32186467 DOI: 10.1080/00015385.2020.1730577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Fabris E, Merlo M, Rapezzi C, Ferrari R, Metra M, Frigerio M, Sinagra G. Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach. Drugs. 2019;79:1543-1556. [PMID: 31432436 DOI: 10.1007/s40265-019-01181-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
42 Schulz M, Griese-Mammen N, Schumacher PM, Anker SD, Koehler F, Ruckes C, Rettig-Ewen V, Wachter R, Trenk D, Böhm M, Laufs U. The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM-CHF randomized controlled trial. ESC Heart Fail 2020. [PMID: 32700409 DOI: 10.1002/ehf2.12904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Piña IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 2021;42:1203-12. [PMID: 33420498 DOI: 10.1093/eurheartj/ehaa1007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
44 Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, Delgado JF, Díez J, Formiga F, Manito N. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med 2021;8:754499. [PMID: 34859070 DOI: 10.3389/fcvm.2021.754499] [Reference Citation Analysis]
45 Herrmann JJ, Beckers-Wesche F, Baltussen LEHJM, Verdijk MHI, Bellersen L, Brunner-La Rocca HP, Jaarsma T, Pisters R, Sanders-Van Wijk S, Rodwell L, Royen NV, Gommans DHF, van Kimmenade RRJ. Fluid REStriction in Heart failure versus liberal fluid UPtake: Rationale and design of the randomised FRESH-UP study. J Card Fail 2022:S1071-9164(22)00544-9. [PMID: 35705150 DOI: 10.1016/j.cardfail.2022.05.015] [Reference Citation Analysis]
46 Ferreira JP. Health-related quality of life scores: ending the minimum 5-point difference as the clinically meaningful threshold. Eur J Heart Fail 2020;22:1006-8. [PMID: 32297433 DOI: 10.1002/ejhf.1822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Nielsen EE, Feinberg JB, Bu FL, Hecht Olsen M, Raymond I, Steensgaard-Hansen F, Jakobsen JC. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Open Heart. 2020;7. [PMID: 33257469 DOI: 10.1136/openhrt-2020-001294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
48 Felker GM, Solomon SD, McMurray JJV, Cleland JGF, Abbasi SA, Malik FI, Zhang H, Globe G, Teerlink JR; COSMIC-HF Investigators. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. Circ Heart Fail 2020;13:e007814. [PMID: 33176437 DOI: 10.1161/CIRCHEARTFAILURE.120.007814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Khandwalla RM, Grant D, Birkeland K, Heywood JT, Fombu E, Owens RL, Steinhubl SR; AWAKE-H. F. Study Investigators. The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure. Am J Cardiovasc Drugs 2021;21:241-54. [PMID: 32978755 DOI: 10.1007/s40256-020-00440-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
50 Ganesananthan S, Shah N, Shah P, Elsayed H, Phillips J, Parkes A, Morgan A, Yousef Z. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study. Open Heart 2020;7:e001305. [PMID: 33020255 DOI: 10.1136/openhrt-2020-001305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Buda V, Prelipcean A, Cozma D, Man DE, Negres S, Scurtu A, Suciu M, Andor M, Danciu C, Crisan S, Dehelean CA, Petrescu L, Rachieru C. An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure. J Clin Med 2022;11:2020. [PMID: 35407628 DOI: 10.3390/jcm11072020] [Reference Citation Analysis]
52 Malfatto G, Ravaro S, Caravita S, Baratto C, Sorropago A, Giglio A, Tomaselli M, Parati G, Villani A. Improvement of functional capacity in sacubitril-valsartan treated patients assessed by cardiopulmonary exercise test. Acta Cardiol 2020;75:732-6. [PMID: 31577528 DOI: 10.1080/00015385.2019.1669317] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
53 Abdin A, Schulz M, Riemer U, Hadëri B, Wachter R, Laufs U, Bauersachs J, Kindermann I, Vukadinović D, Böhm M. Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials. ESC Heart Fail 2022. [PMID: 35921043 DOI: 10.1002/ehf2.14097] [Reference Citation Analysis]
54 Bouabdallaoui N, Rouleau J. Evolving towards a more realistic approach to the importance of left ventricular ejection fraction and sex in heart failure and its therapy. Eur J Heart Fail 2020;22:800-3. [PMID: 32227549 DOI: 10.1002/ejhf.1805] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Jankowska EA, Ponikowski P. Dilemmas on diagnosis and treatment of iron deficiency in patients after an episode of acute heart failure. Eur Heart J 2021:ehab839. [PMID: 34888632 DOI: 10.1093/eurheartj/ehab839] [Reference Citation Analysis]